Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Jiangsu Hengrui Medicine describes bisulfate salt of JAK inhibitor for rheumatoid arthritis

Dec. 31, 2014

Neovacs' phase IIb trial of TNF-Kinoid in rheumatoid arthritis misses endpoint

Dec. 16, 2014

Animal model of osteochondromagenesis highlights role of NFATc1

Dec. 16, 2014

Safety and clinical efficacy of CreaVax-RA tested in patients with RA

Dec. 15, 2014

FDA grants conditional approval to Cytori Cell Therapy for trial in scleroderma

Dec. 12, 2014

Phase II results presented for clazakizumab in patients with active psoriatic arthritis

Dec. 11, 2014

AT-001 given U.S. orphan drug designation for X-linked myotubular myopathy

Dec. 10, 2014

Jiangsu Simcere Pharmaceutical divulges novel BTK inhibitors

Dec. 10, 2014

Lilly and Incyte report topline results from phase III trial of baricitinib

Dec. 10, 2014

Zydus Cadila launches adalimumab biosimilar in India

Dec. 10, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...